Sanara Medtech Company Top Insiders

SMTI Stock  USD 35.94  0.42  1.16%   
Sanara Medtech's insiders are aggressively selling. The analysis of insiders' sentiment of trading Sanara Medtech stock suggests that almost all insiders are panicking at this time. Sanara Medtech employs about 107 people. The company is managed by 15 executives with a total tenure of roughly 21 years, averaging almost 1.0 years of service per executive, having 7.13 employees per reported executive.
Shawn Bowman  President
President Wound Care Division
Zachary Fleming  President
President Surgical Division

Sanara Medtech's Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2022-11-08Zachary B FlemingDisposed 417 @ 33View
2022-11-04Zachary B FlemingDisposed 563 @ 33View
2022-11-02Zachary B FlemingDisposed 20 @ 33.02View
2022-09-22Shawn M BowmanDisposed 1000 @ 27.89View
2022-07-05Zachary B FlemingDisposed 265 @ 21.45View
2022-06-28Zachary B FlemingDisposed 69 @ 21View
2022-06-24Zachary B FlemingDisposed 457 @ 21View
2022-06-17Shawn M BowmanDisposed 1000 @ 20.02View
Monitoring Sanara Medtech's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanara Medtech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.

Sanara Medtech's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Sanara Medtech's future performance. Based on our forecasts, it is anticipated that Sanara will maintain a workforce of under 110 employees by January 2025.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Sanara Medtech Management Team Effectiveness

The company has return on total asset (ROA) of (0.0508) % which means that it has lost $0.0508 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2028) %, meaning that it created substantial loss on money invested by shareholders. Sanara Medtech's management efficiency ratios could be used to measure how well Sanara Medtech manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.18. The current Return On Capital Employed is estimated to decrease to -0.07. As of now, Sanara Medtech's Total Current Assets are increasing as compared to previous years. The Sanara Medtech's current Intangible Assets is estimated to increase to about 47.2 M, while Non Currrent Assets Other are forecasted to increase to (18.1 M).
The Sanara Medtech's current Common Stock Shares Outstanding is estimated to increase to about 8.7 M, while Net Loss is forecasted to increase to (6.8 M).

Sanara Medtech Workforce Comparison

Sanara Medtech is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 97,707. Sanara Medtech adds roughly 107 in number of employees claiming only tiny portion of equities under Health Care industry.

Sanara Medtech Profit Margins

The company has Profit Margin (PM) of (0.11) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.06) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.06.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.920.8792
Sufficiently Up
Slightly volatile

Sanara Medtech Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sanara Medtech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sanara Medtech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Sanara Medtech insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
0.2857
2
7
 17,343 
 5,075 
2023-06-01
10.0
10
1
 38,766 
 1,000.00 
2023-03-01
0.5
4
8
 15,351 
 4,599 
2022-09-01
2.6667
8
3
 37,704 
 1,750 
2021-12-01
0.2222
4
18
 13,843 
 7,275 
2021-09-01
1.0
1
1
 5,339 
 1,000.00 
2020-03-01
1.8333
33
18
 5,096,143 
 2,362,193 
2019-12-01
1.5
3
2
 1,204,820 
 0.00 
2018-03-01
2.0
6
3
 70,270,577 
 29,852 
2016-06-01
1.0
1
1
 1,500,000 
 1,500,000 
2015-03-01
1.0
1
1
 750,000 
 750.00 
2004-12-01
1.0
3
3
 36,250 
 36,250 
2004-09-01
8.0
8
1
 7,733,553 
 3,750 

Sanara Medtech Notable Stakeholders

A Sanara Medtech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sanara Medtech often face trade-offs trying to please all of them. Sanara Medtech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sanara Medtech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ronald NixonExecutive Chairman of the BoardProfile
Shawn BowmanPresident Wound Care DivisionProfile
Seth YonPresident CommercialProfile
David StrasfeldPresident HealingProfile
Zachary FlemingPresident Surgical DivisionProfile
Rebecca McmahonPresident DevelopmentProfile
Michael McNeilCFO SecretaryProfile
Bill FitzgeraldCompliance OfficerProfile
Jacob WaldropChief OfficerProfile
Callon NicholsDirector RelationsProfile
Jane ForeChief OfficerProfile
Tricia MattesonDirector MarketingProfile
Tyler PalmerChief OfficerProfile
Carla DayDirector ServicesProfile
FACHM FAPWCAPres ServicesProfile

About Sanara Medtech Management Performance

The success or failure of an entity such as Sanara Medtech often depends on how effective the management is. Sanara Medtech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sanara management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sanara management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.17)(0.18)
Return On Capital Employed(0.07)(0.07)
Return On Assets(0.06)(0.06)
Return On Equity(0.10)(0.10)

Sanara Medtech Workforce Analysis

Traditionally, organizations such as Sanara Medtech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sanara Medtech within its industry.

Sanara Medtech Manpower Efficiency

Return on Sanara Medtech Manpower

Revenue Per Employee607.4K
Revenue Per Executive4.3M
Net Loss Per Employee40.2K
Net Loss Per Executive286.9K
Working Capital Per Employee49K
Working Capital Per Executive349.2K

Complementary Tools for Sanara Stock analysis

When running Sanara Medtech's price analysis, check to measure Sanara Medtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanara Medtech is operating at the current time. Most of Sanara Medtech's value examination focuses on studying past and present price action to predict the probability of Sanara Medtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanara Medtech's price. Additionally, you may evaluate how the addition of Sanara Medtech to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Commodity Directory
Find actively traded commodities issued by global exchanges
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA